| Cav-α1 | Pharmacology | Tissue affected | Syndromes associated |
|---|---|---|---|
|
Cav1.1 Cav1.2 Cav1.3 Cav1.4 |
Dihydropyridne, Benzothiazepine, Phenylalkylamine, TaiCatoxin, Calciseptine Calcicludine, FS-2 | skeletal musclesubiquitary ubiquitary retina |
Hypokalemic periodic paralysis type 1 (HypoPP1), malignant hyperthermia type 5 (MHS5) Timothy syndrome (LQT8, epilepsy) Not known x-linked conginital stationary night blindness 2 (xCSNB2), X-linked cone-rod dystrophy type 3 (CORDX3) |
|
Cav2.1
Cav2.2 Cav2.3 |
ω-Agatoxin IVA
ω-Conotoxin GVIA SNX-482, Ni2+ |
CNS
CNS/PNS CNS/PNS |
Absence-epilepsy, episodic ataxia type 2, spinocerebellar ataxia type 6, familial hemiplegic migraine, Lambert-Eaton myastenie-Syndrome
Lambert-Eaton myastenie-syndrome Not known |
| Cav3.1 Cav3.2 Cav3.3 | Mibefradil, Kurtoxin, Ni2+ | CNS/PNS CNS/heart CNS |
Not known Absence-epilepsy (CAE), Autism spectrum disorders (ASD) Not known |